Alnylam Pharmaceuticals, Inc. (ALNY) fair value analysis
Nasdaq · Updated 2026-10-19
ALNY price how computed
Valuation status
Awaiting full valuationALNY does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $231.83
- Sector
- Healthcare
- 12-month range
- $205.48–$481.59
- Market cap
- $31B
- From 52-week high
- -51.9%
- Shares outstanding
- 134M
- Rank in Healthcare by quality score
- #22 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes medicines based on RNA interference technology to treat rare genetic diseases and other conditions. The company operates globally with operations across the United States, Europe, and other international markets.
ALNY currently ranks #22 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $31B
- P/E (trailing)
- 32x
- Revenue (TTM)
- $4.8B
- Net margin
- 16.8%
- EPS (TTM)
- $7.35
- Gross margin
- 76.9%
- Debt / equity
- 0.94
- Revenue growth (3-yr avg)
- 24.0%
- Shares outstanding
- 134M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 45 · neutral
- 50-day average
- $238.41
- 200-day average
- $294.30
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-16.0%)
2026-03 ▲ beat (+35.4%)
2025-12 ▼ miss (-16.7%)
2025-09 ▲ beat (+65.7%)
2025-06 ▲ beat (+113.3%)
2025-03 ▲ beat (+97.3%)
2024-12 ▲ beat (+142.9%)
2024-09 ▼ miss (-28.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 22 buy · 7 hold · 0 sell (29 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $369
- Target vs last price
- +59.2%
What our data shows for ALNY
- Our model validated 2 trailing price-to-earnings windows for ALNY, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $205.48–$481.59.
- The 14-day relative strength index sits at a neutral 45.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ALNY's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ALNY news
TickrTrends' derived news-sentiment signal for ALNY is currently leaning positive, computed from recent coverage.
- Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? (insidermonkey.com, 2026-10-20)
- ALNY Maintained by Wells Fargo -- Price Target Lowered to $253 (gurufocus.com, 2026-10-14)
- Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) (seekingalpha.com, 2026-09-28)
More ALNY news
- Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) (seekingalpha.com, 2026-09-26)
- Alnylam Pharmaceuticals, Inc. RNAi Roundtable Call Transcript (gurufocus.com, 2026-09-17)
What people are saying
Follow the ALNY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' quality grade for ALNY improved from B to A this week, indicating an enhanced assessment of the company's fundamental characteristics within the Healthcare sector. The valuation verdict remains under review as the firm awaits completion of its full valuation analysis.
- 2026-10-05 — ALNY's 50/200-day trend state shifted from mixed to downtrend this week, indicating that shorter-term price momentum has weakened relative to longer-term movement patterns. The Healthcare sector company remains in an awaiting full valuation verdict status, meaning comprehensive valuation analysis is still pending. This trend deterioration represents a notable technical change for the stock compared to the prior week's mixed positioning.
- 2026-09-28 — ALNY's 50/200-day trend state shifted from downtrend to mixed this week, indicating a potential transition in the stock's momentum dynamics. The Healthcare sector company remains under an awaiting full valuation verdict, suggesting that comprehensive valuation metrics are still being compiled for investor consideration.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ALNY stock undervalued?
ALNY does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ALNY's TickrTrends verdict?
ALNY is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does ALNY compare to other Healthcare stocks?
ALNY ranks #22 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ALNY overbought or oversold?
ALNY's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ALNY report earnings next?
ALNY's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does ALNY usually beat earnings estimates?
Over its last 8 reported quarters ALNY beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ALNY?
Of 29 analysts covering ALNY, 22 rate it a buy, 7 a hold and 0 a sell - buy-leaning, with a consensus price target of $369 (+59.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.